Candidalysin, a fungal toxin that drives yeast vaginitis
Candidalysin: a key mediator of Candida vaginitis immunopathology
The project will find out whether different versions of a Candida toxin cause inflammation in women with yeast vaginitis and if vaccines or new chemical compounds can reduce infection and symptoms.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project ID | NIH-11248797 on NIH RePORTER |
What this research studies
From a patient's perspective, researchers are studying candidalysin, a toxin made by Candida albicans that appears to trigger the pain and inflammation of yeast vaginitis. They will compare toxin variants found in clinical samples and change single amino acids to map which parts cause inflammation. The team will test those variants and vaccine approaches in laboratory and animal models to see if immune responses can prevent symptoms. They will also screen new thiobenzoate chemical compounds for the ability to stop fungal growth or reduce inflammation.
Who could benefit from this research
Good fit: People most likely to benefit are women who experience recurrent or severe vulvovaginal candidiasis (recurrent yeast vaginitis).
Not a fit: Those whose vaginal symptoms are caused by non-Candida problems (for example bacterial vaginosis or non-infectious vulvar conditions) are unlikely to benefit from these Candida-targeted approaches.
Why it matters
Potential benefit: If successful, the work could lead to vaccines or new treatments that reduce inflammation and clear Candida infections more quickly, easing symptoms for people with yeast vaginitis.
How similar studies have performed: Prior laboratory work has shown candidalysin drives inflammation and some vaccine or antifungal approaches have shown promise in animal models, but human testing remains limited.
Where this research is happening
Memphis, United States
- University of Tennessee Health Sci Ctr — Memphis, United States (Active)
Researchers
- Principal investigator: Peters, Brian M — University of Tennessee Health Sci Ctr
- Study coordinator: Peters, Brian M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.